B
Bullisch
Bullisch · 25%BLRX
$4.97
Szenariopreis
$1.730
-0.037 (-2.15%)Zum Schluss
Loading chart…
- Hoch
- 1.750
- Eröffnung
- 1.715
- Volumengewichteter Durchschnittskurs
- 1.73
- Volumen
- 7.76K
- Marktkap.
- 45.57M
- Tief
- 1.709
- Umsatz
- 13.42K
- EV/EBITDA, TTM
- -0.45
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
KI-Analyse of BioLine RX Ltd (BLRX)
VerkaufenBioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.
Analystenbewertungen (4)
+593.64% Aufwärtspotenzial
Kaufen
4 Kaufen
0 Halten
0 Verkaufen
Aktuell: 1.73
Tief
12.00
Durchschnitt
12.00
Hoch
12.00
Jones Trading
Halten
—
2025-04-02
Jones Trading
2025-04-02
Kursziel
—
Halten
HC Wainwright & Co.
Starker Kauf
$26
2025-03-31
HC Wainwright & Co.
2025-03-31
Kursziel
$26
Starker Kauf
HC Wainwright & Co.
Starker Kauf
$9
2024-11-25
HC Wainwright & Co.
2024-11-25
Kursziel
$9
Starker Kauf
HC Wainwright & Co.
Starker Kauf
$21
2024-11-06
HC Wainwright & Co.
2024-11-06
Kursziel
$21
Starker Kauf
Jones Trading
Starker Kauf
$2
2024-09-04
Jones Trading
2024-09-04
Kursziel
$2
Starker Kauf
Bewertungskennzahlen
Das aktuelle erwartete KGV von BioLine RX Ltd (BLRX) beträgt 93.46, verglichen mit dem 5-Jahres-Durchschnitt von 15.21.
Alphio-AI-Kursszenarien für BLRX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
9.010-23PRnewswireGLIX1 Shows Significant Synergy with PARP Inhibitors
8.510-08PRnewswireBioLineRx and Hemispherian to Present GLIX1 at SNO Annual Meeting
5.009-01NASDAQ.COMLifeward Appoints New CEO and CFO Amid Leadership Transition
9.508-31Yahoo FinanceBioLineRx Reports Q2 2026 Earnings with Increased R&D Expenses
8.508-31PRnewswireBioLineRx Reports Significant Progress in GLIX1 Clinical Trials
BLRX FAQ – beantwortet von Alphio AI
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment. It operates in the Healthcare sector.
BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.
4 analysts cover BLRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.